COLLABORATIONS PHARMACEUTICALS INC
Fuquay Varina, NC · Biotech · Private
Recombinant palmitoyl-protein thioesterase-1 (rhPPT1) enzyme replacement therapy for CLN1 disease
collaborationspharma.com →- Grants
- $18M
- 30 awards
- Sector median: 1
- Raised
- —
- No Form D on record
- Contracts
- —
- No federal contracts on record
- Patents
- 21
- 2 granted · 19 pending
- Sector median: 2
Capital Timeline
Federal ↑Equity ↓20162018202020222024
| Date | Event | Source | Amount |
|---|---|---|---|
| Federal grant | Department of Health and Human Services · Phase I · Optimization of small molecule triazine antituberculars for in vivo efficacy | $149,388 | |
| Federal grant | Department of Health and Human Services · Phase I · Centralized assay datasets for modelling support of small drug discovery organizations | $149,999 | |
| Federal grant | Department of Health and Human Services · Phase I · Structure-guided optimization of an in vivo active small molecule antitubercular targeting KasA | $224,998 | |
| Federal grant | Department of Health and Human Services · Phase II · Centralized assay datasets for modelling support of small drug discovery organizations | $694,172 | |
| Federal grant | Department of Health and Human Services · Phase I · Enzyme Replacement Therapy For Infantile Onset Neuronal Ceroid Lipofuscinoses | $229,560 | |
| Federal grant | Department of Health and Human Services · Phase I · Enzyme Replacement Therapy For Infantile Onset Neuronal Ceroid Lipofuscinoses | $411,523 | |
| Federal grant | Department of Health and Human Services · Phase I · Enzyme Replacement Therapy For Infantile Onset Neuronal Ceroid Lipofuscinoses | $127,300 | |
| Federal grant | Department of Health and Human Services · Phase I · MegaTrans – human transporter machine learning models | $210,712 | |
| Federal grant | Department of Health and Human Services · Phase I · Enzyme Replacement Therapy For Infantile Onset Neuronal Ceroid Lipofuscinoses | $54,663 | |
| Federal grant | Department of Health and Human Services · Phase II · Centralized assay datasets for modelling support of small drug discovery organizations | $692,845 | |
| Federal grant | Department of Health and Human Services · Phase II · Centralized assay datasets for modelling support of small drug discovery organizations | $188,759 | |
| Federal grant | Department of Health and Human Services · Phase I · MegaPredict for predicting natural product uses and their drug interactions | $68,862 | |
| Federal grant | Department of Health and Human Services · Phase I · MegaPredict for predicting natural product uses and their drug interactions | $224,548 | |
| Federal grant | Department of Health and Human Services · Phase I · MegaTox for analyzing and visualizing data across different screening systems | $224,548 | |
| Federal grant | Department of Health and Human Services · Phase I · MegaPredict for predicting natural product uses and their drug interactions | $155,686 | |
| Federal grant | Department of Health and Human Services · Phase I · MegaTox for analyzing and visualizing data across different screening systems | $124,915 | |
| Federal grant | Department of Health and Human Services · Phase II · Centralized assay datasets for modelling support of small drug discovery organizations | $855,127 | |
| Federal grant | Department of Health and Human Services · Phase I · Machine learning approaches to predict Acetylcholinesterase inhibition | $256,385 | |
| Federal grant | Department of Health and Human Services · Phase I · New therapeutic approaches to identifying molecules for opioid abuse treatment | $256,220 | |
| Federal grant | Department of Health and Human Services · Phase II · Manufacture of an intracerebroventricular Enzyme Replacement Therapy for CLN1 Batten Disease | $1,499,923 | |
| Federal grant | Department of Health and Human Services · Phase II · Manufacture of an intracerebroventricular Enzyme Replacement Therapy for CLN1 Batten Disease | $2,999,846 | |
| Federal grant | Department of Health and Human Services · Phase II · Centralized assay datasets for modelling support of small drug discovery organizations | $854,677 | |
| Federal grant | Department of Health and Human Services · Phase II · MegaTox for analyzing and visualizing data across different screening systems | $855,003 | |
| Federal grant | Department of Health and Human Services · Phase II · MegaTrans – human transporter machine learning models | $864,767 | |
| Federal grant | Department of Health and Human Services · Phase II · Manufacture of an intracerebroventricular Enzyme Replacement Therapy for CLN1 Batten Disease | $1,499,923 | |
| Federal grant | Department of Health and Human Services · Phase II · MegaTox for analyzing and visualizing data across different screening systems | $855,003 | |
| Federal grant | Department of Health and Human Services · Phase II · MegaTrans – human transporter machine learning models | $864,767 | |
| Federal grant | Department of Health and Human Services · Phase I · Preclinical development of a Nipah Virus inhibitor | $295,096 | |
| Federal grant | Department of Health and Human Services · Phase II · Machine learning approaches to predict Acetylcholinesterase inhibition and model applications | $727,312 | |
| Federal grant | Department of Health and Human Services · Phase II · Machine learning approaches to predict Acetylcholinesterase inhibition and model applications | $1,317,335 |
Federal grant · SBIR/STTR
Peer position
| # | Company | Contracts | Disclosed equity |
|---|---|---|---|
| 3365 | Adipo Therapeutics, LLC | — | $6.0M |
| 3366 | Adcendo | — | — |
| 3367 | SYNERGYS BIOTHERAPEUTICS, INC. | — | — |
| 3368 | COLLABORATIONS PHARMACEUTICALS INC | — | — |
| 3369 | Centivax Inc | — | — |
| 3370 | SPERAGEN, INC. | — | — |
| 3371 | SERVA ENERGY, INC. | — | $7.1M |
Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.
Patents
- Vandetanib Reduces Inflammatory Cytokines And Ameliorates COVID-19application
- Uv-vis Spectra Predictionapplication
- Use Of Pyronaridine, Tilorone, And Quinacrine Against Marburg Virus And Other Virus Infectionsapplication
- The Antiviral Drug Tilorone Is A Potent And Selective Inhibitor Of Acetylcholinesteraseapplication
- Use Of Pyronaridine, Tilorone, And Quinacrine Against Marburg Virus And Other Virus Infectionsgranted
- Methods and Compositions for Modulating Beta-Amyloid/Alpha7-nAChR Interactionsgranted
- Vandetanib Reduces Inflammatory Cytokines And Ameliorates COVID-19application
- Uv-vis Spectra Predictionapplication
- Vandetanib Reduces Inflammatory Cytokines And Ameliorates COVID-19 In Infected Miceapplication
- The Antiviral Drug Tilorone Is A Potent And Selective Inhibitor Of Acetylcholinesteraseapplication
- Antiviral Drug Tilorone Is A Potent And Selective Inhibitor Of Acetylcholinesteraseapplication
- Use Of Pyronaridine, Tilorone, And Quinacrine Against Marburg Virusapplication
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.